These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 26463349)

  • 1. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
    Nobili V; Alisi A; Musso G; Scorletti E; Calder PC; Byrne CD
    Crit Rev Clin Lab Sci; 2016; 53(2):106-20. PubMed ID: 26463349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3 Fatty Acids and Fatty Liver Disease in Children.
    Corte CD; Iasevoli S; Strologo AD; Sanseviero M; Nobili V
    Adv Food Nutr Res; 2018; 85():59-77. PubMed ID: 29860977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
    Scorletti E; Byrne CD
    Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
    Kelley NS
    Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
    Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fish oil alleviated high-fat diet-induced non-alcoholic fatty liver disease via regulating hepatic lipids metabolism and metaflammation: a transcriptomic study.
    Yuan F; Wang H; Tian Y; Li Q; He L; Li N; Liu Z
    Lipids Health Dis; 2016 Feb; 15():20. PubMed ID: 26832365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD.
    Sabinari I; Horakova O; Cajka T; Kleinova V; Wieckowski MR; Rossmeisl M
    Physiol Res; 2024 Aug; 73(Suppl 1):S295-S320. PubMed ID: 39016154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease.
    Alberti G; Gana JC; Santos JL
    Nutrients; 2020 Nov; 12(11):. PubMed ID: 33212947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives.
    Mitrovic M; Sistilli G; Horakova O; Rossmeisl M
    Eur J Clin Invest; 2022 Mar; 52(3):e13650. PubMed ID: 34291454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
    Scorletti E; Byrne CD
    Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
    Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
    J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids.
    de Castro GS; Calder PC
    Clin Nutr; 2018 Feb; 37(1):37-55. PubMed ID: 28139281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
    J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.
    Chen LH; Wang YF; Xu QH; Chen SS
    Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.
    Di Minno MN; Russolillo A; Lupoli R; Ambrosino P; Di Minno A; Tarantino G
    World J Gastroenterol; 2012 Nov; 18(41):5839-47. PubMed ID: 23139599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long chain omega-3 polyunsaturated fatty acids in pediatric metabolic syndrome.
    Pacifico L; Giansanti S; Gallozzi A; Chiesa C
    Mini Rev Med Chem; 2014; 14(10):791-804. PubMed ID: 25307311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
    Spooner MH; Jump DB
    Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.